Germany
· Delayed Price · Currency is EUR GSK plc Company Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines.
It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
It has a collaboration agreement with CureVac to develop vaccines for influenza and COVID-19, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
| Country | United Kingdom |
| Founded | 1715 |
| Industry | Pharmaceutical Preparations |
| Employees | 68,629 |
| CEO | Emma Walmsley |
Contact Details
Address: 79 New Oxford Street London, WC1A 1DG United Kingdom | |
| Phone | 44 20 8047 5000 |
| Website | gsk.com |
Stock Details
| Ticker Symbol | GS71 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Emma Walmsley | Chief Executive Officer |
| Julie Brown | Chief Financial Officer |